Prediagnostic aspirin use was not found to be associated with a reduction in breast cancer-specific mortality; however, effect modification by lymph node status was observed and mortality was found to be reduced by approximately one-half among aspirin users with lymph node-negative disease. This according to a cohort study of 2,925 postmenopausal women (total of 18,073 person-years) diagnosed with stage I to III breast cancer from 1993 to 2009 in the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Prediagnostic aspirin use was identified in 1,274 women. Researchers found:
• Prediagnostic aspirin use was not found to be associated with lower breast cancer-specific mortality (HR=0.95).
• Aspirin use was found to be associated with lower breast cancer-specific mortality, however, among women with lymph node-negative tumors (HR=0.54), but not those with lymph node-positive tumors (HR=1.41).
• Tests for interaction were found to be statistically significant.
• No association was noted between aspirin use and lymph node status.
Citation: Bradley MC, Black A, Freedman AN, Barron TI. Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. [Published online ahead of print May 3, 2016]. Cancer. doi:10.1002/cncr.30004.